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Available online 19 March 2013Abstractb-Glucans are known for their ability to trigger both protective and damaging immune responses. Here we have explored the role of the beta-
glucan receptor Dectin-1 in archetypical models of protective and non-protective immunomodulation induced by beta-glucan rich ligands. In the
first model, we explored the role of Dectin-1 in the ability of soluble purified b-glucans to mediate protection against systemic Staphylococcus
aureus infection in mice. In the second model, we explored the role of Dectin-1 in zymosan induced multiple organ dysfunction syndrome. In
both cases, these b-glucan rich compounds had marked effects in vivo which were unaltered by Dectin-1 deficiency, suggesting that this receptor
has a redundant role in these murine models.
 2013 Institut Pasteur. Published by Elsevier Masson SAS.
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b-Glucans are glucose polymers that are found in fungal
cell walls, plants and some bacteria [1]. b-Glucans are known
for their ability to activate leukocytes, and have been of
considerable interest as immune modulators, promoting anti-
tumorigenic and anti-microbial activities [2]. Administration
of these carbohydrates to mice, for example, has been shown
to protect against infection with Staphylococcus aureus [3], a
gram positive opportunistic pathogen that causes soft tissue
infections that can lead to invasive disease and sepsis. How-
ever, exaggerated inflammatory response that can be induced
by b-glucans in certain circumstances can also have* Corresponding author. Section of Immunology and Infection, Division of
Applied Medicine, Institute of Medical Sciences, Foresterhill, University of
Aberdeen, Aberdeen AB25 2ZD, UK.
E-mail address: gordon.brown@abdn.ac.uk (G.D. Brown).
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Open accesdetrimental effects, especially if these carbohydrates are
administered in particulate form. One relevant example is the
ability of a high dose of the b-glucan rich particle zymosan to
induce multiple organ dysfunction syndrome (MODS) in mice,
which is characterized by uncontrolled systemic inflammation
leading to a deterioration of function in several organs [4].
How b-glucans actually mediate these effects on immune
function is still unclear.
Several receptors for b-glucans have been identified,
including Dectin-1, a receptor we have shown to be expressed
by various immune cells including, dendritic cells, monocytes,
macrophages, neutrophils and a subset of T cells [5]. This
pattern recognition receptor contains a single extracellular
lectin-like carbohydrate recognition domain and a cytoplasmic
tail with an immunoreceptor tyrosine-based activation-like
motif (ITAM-like), which can initiate intracellular signalling
upon engagement of b-glucans [5]. The recognition of b-glu-
cans by Dectin-1 induces numerous cellular responses,s under CC BY license.
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arachidonic acid metabolites, and the induction of a number of
cytokines and chemokines [5]. We and others have shown that
through the recognition of b-glucans, Dectin-1 plays a key role
in anti-fungal immunity in both mouse and humans [6]. In this
study, we have investigated the involvement of Dectin-1 in both
protective and non-protective models of immunomodulation
induced by b-glucan rich ligands.
2. Materials and methods2.1. MiceAge-matched (8e10 week-old) male wild-type and
Clec7a/ mice on 129/Sv [7] or C57BL/6 background (mice
were backcrossed for at least nine generations) were used in
these experiments, as indicated. All mice were obtained from
the specific-pathogen-free facility of the University of Cape
Town. All animal experiments were repeated at least once, and
were performed according to animal care and welfare pro-
tocols approved by the University of Cape Town Animal
Research ethics committee. All experiments utilized a mini-
mum of six mice per group.2.2. Staphylococcus aureus infection modelS. aureus (ATCC 25923) was obtained from the Medical
Microbiology Laboratory of the University of Cape Town.
Bacteria were cultured for 6 h in LB medium, washed in PBS
and frozen in aliquots at 80 C. These aliquots were subse-
quently used for infection into animals. Colony forming units
(CFU) were determined by serial dilution onto LB-agar plates.
For infections, mice were infected systemically with
5  106 CFU of the bacteria (day 0). In some animals, b-
glucans were administered i.v. on day-7 and day-4 with 200 ml
containing 1 mg of soluble b-glucan diluted in PBS. Clinical
grade highly purified soluble b-glucans were kindly provided
by Biotec Pharmacon, Norway. Endotoxin levels were below
0.05 EU/ml. Animals were subsequently monitored and
sacrificed when they became moribund or had greater than
20% weight loss. Differences in the gross pathologies of the
kidneys from infected mice at day 11 were determined by
staining 10% formaldehyde-fixed organ sections with Hae-
matoxylin and Eosin (H&E) stains.2.3. MODS modelFor these experiments, we used a model of zymosan-
induced generalized inflammation, as described [4,8]. In
brief, mice were pre-treated with 40 mg lipopolysaccharide
(LPS, Sigma), administered intraperitoneally (ip), 6 days
before the i.p. administration of 17 mg of the b-glucan-rich
fungal cell-wall-derived particle, zymosan A. Zymosan A
(Sigma) was prepared by suspension in paraffin (Sigma),
disaggregation by sonication for 60 min, followed by heating
for 90 min at 100 C. Animals were monitored for survival, as
described above.2.4. StatisticsAll numerical data were analysed using GraphPad Prism 4
software. Survival data were analysed with the log rank test.
Results were considered statistically significant with P values
of less than 0.05.
3. Results3.1. The b-glucan mediated protection against S. aureus
infection is Dectin-1 independentThe administration of soluble b-glucans has been shown to
increase resistance to S. aureus infection in mice [9,10]. To
explore the role of Dectin-1, a major leukocyte receptor for
these carbohydrates, we established a systemic model of
infection with S. aureus which resulted in rapid weight loss
and more than 50% mortality in untreated mice (Fig. 1A, B).
Moreover, infection of these animals led to marked patho-
logical changes in renal cortex and renal parenchyma, char-
acterized by abscess formation and extensive inflammatory
cell infiltration (Fig. 1C) [10]. As previously reported [10],
pre-treatment of mice with a highly purified, clinical grade,
soluble b-glucan prior to infection with S. aureus, significantly
increased the ability of wild-type mice to resist the infection
(Fig. 1A), which corresponded to reduced weight loss
(Fig. 1B) and reduced pathology in the kidneys (Fig. 1C).
However, pre-treated mice lacking Dectin-1 showed similarly
enhanced survival and reduction in weight loss and kidney
pathology (Fig. 1AeC). Moreover, we did not detect any
difference between treated wild-type and Dectin-1 deficient
mice in the levels of several cytokines known to be influenced
by Dectin-1 [5] (Fig. 1D). Thus these results indicate that
while pre-treatment of mice with b-glucans can provide pro-
tection against systemic S. aureus infections, Dectin-1 plays a
redundant role in this process.3.2. Dectin-1 is not involved in zymosan-induced
multiple organ dysfunction syndrome (MODS)The administration of a single high dose of zymosan in
mice induces the onset of multiple organ dysfunction syn-
drome (MODS), and is a well-known animal model for
studying the underlying mechanisms involved in the devel-
opment of this disease [4]. Zymosan is a cell wall extract from
Saccharomyces cerevisiae that is rich in biologically active
beta-glucans and we have previously shown that Dectin-1 is
the main receptor for unopsonised zymosan on leukocytes,
triggering several cellular responses to these particles [11]. To
determine whether Dectin-1 was involved in zymosan-induced
MODS, we compared the development of the disease in wild-
type and Dectin-1-deficient mice.
Following the administration of a single dose of zymosan,
both groups of animals showed similar patterns of survival and
a typical three-phasic disease known to be associated with this
inflammatory model [4]. In the first phase, we observed
w20% mortality in both groups within the first 2 days after
Fig. 1. b-Glucan mediated resistance against S. aureus infection is independent of Dectin-1. Wild-type (wt) and clec7A/ 129Sv mice were left untreated or
treated intravenously with 1 mg of soluble b-glucan at day-7 and -4 prior to infection with 5  106 CFU S. aureus, as indicated. Animals were monitored daily for
mortality (A) and percentage weight gain (B). *, P < 0.05. n ¼ 8e10 animals per group. (C) H&E histopathology of kidneys from infected animals at day 11, as
indicated. (D) Levels of various cytokines in the kidneys of treated and infected mice at day 11, as indicated. n ¼ 6 animals per group. ns, not significant.
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illness was also characterized by symptoms such as diarrhoea,
ruffled fur, lethargic behaviour and weight loss (Fig. 2B and
data not shown). Between day 3 and 7 (the second phase), the
surviving animals in both groups appeared to return to normal
health, as reflected by the display of typical behaviour, smooth
fur and normal faeces. No mortality was observed in this
phase, and mice started gaining weight (Fig. 2B and data not
shown). The third phase which is thought to resemble clinical
progression of MODS in humans [4], occurred after day 8,
with mortality and a re-emergence of clinical symptoms
(Fig. 2 and data not shown). Both the wild-type and Dectin-1
deficient mice presented with further 40e45% mortality from
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Fig. 2. The development of zymosan induced MODS occurs independently of
Dectin-1. Survival (A) and percentage weight gain (B) of wild type (wt) and
clec7A/ C57BL/6 mice (n ¼ 28 animals per group) following the admin-
istered of 17 mg of zymosan (day 0). Mice were pre-treated with 40 mg LPS, as
described in the materials and methods. Survival data were analysed with the
log rank test. ns, not significant.progression in the Dectin-1 deficient mice indicates that this
receptor plays a redundant role in zymosan induced MODS.
4. Discussion
b-Glucans are potent immunomodulators that have been
demonstrated to possess both therapeutic benefits and well as
detrimental effects when administered in vivo, depending on
the disease and experimental model [1,2]. The ability of these
carbohydrates to drive these responses is thought to stem, at
least in part, from their capacity to trigger the activation of
leukocytes [2]. In line with this, recent studies have shown that
b-glucans mediate epigenetic reprogramming of circulating
monocytes, thus inducing partial protection to reinfection in a
T/B-cell independent manner, in a process that has been called
trained immunity [12]. While several receptors for these car-
bohydrates have been identified [13], Dectin-1 has been shown
to be the major receptor for b-glucans on leukocytes and is
capable of mediating the biological activities of these carbo-
hydrates in vitro [11,14]. Importantly, the ability of Dectin-1 to
recognize b-glucans and induce cellular responses is influ-
enced by the structure of these carbohydrates and the cell type
expressing this receptor [15e19].
In this study, we have examined the role of Dectin-1 in two
archetypical murine models that display either the beneficial
or the detrimental effects of b-glucan rich ligands. In the first
model, we determined the contribution of Dectin-1 to the
protective effect of highly purified soluble b-glucans during
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that the administration of these compounds can significantly
enhance resistance to infection and the survival of mice
following infection with this Gram-positive bacterium
[3,9,10]. Consistent with these prior observations, we found
that pre-treatment of mice with intravenously administered
soluble b-glucans significantly enhanced their ability to resist
subsequent systemic infection with S. aureus (Fig. 1). How-
ever, the ability of b-glucans to protect mice was not dimin-
ished by Dectin-1 deficiency, indicating that this receptor was
not involved in mediating these protective responses in vivo.
While we and others have shown that Dectin-1 can recognize
soluble b-glucans in vitro, recent evidence from the Underhill
laboratory suggests that productive intracellular signalling
from Dectin-1 can only occur following recognition of large b-
glucan complexes and the exclusion of inhibitory phosphatases
from the “phagocytic synapse” [15e17]. Moreover, Dectin-1
involvement in a b-glucan-mediated antitumour model was
also recently shown to depend on the nature of the b-glucan
employed [20]. Thus the redundant role of Dectin-1 in the
model tested in our study is likely to reflect the inability of
soluble carbohydrates to sufficiently activate this receptor
in vivo. On the other hand, soluble b-glucans are able to
induce protection in a Gram-positive sepsis model, as shown
here. How b-glucans mediate their protective effects is still
unclear, but may involve some sort of leukocyte priming [2].
Indeed, it has been recently shown that the non-specific pro-
tective effects induced by b-glucans in vitro involve changes at
the level of histone methylation and functional reprogramming
of monocytes [12], and whether similar molecular mecha-
nisms are able to mediate the protective effects of soluble b-
glucans in vivo awaits further clarification.
In the second model, we explored the involvement of
Dectin-1 in a widely used model of generalized inflammation,
induced by the intraperitoneal administration of unopsonised
zymosan, which is thought to reflect MODS in humans [4].
However, despite considerable in vitro evidence for a role of
Dectin-1 in mediating leukocyte responses to zymosan [7,11],
we observed no differences in the onset of MODS when this
model was tested in Dectin-1-deficient mice. While the rea-
sons for this are not yet fully understood, recent studies
suggest that inflammatory responses induced following the
activation of complement by particulate b-glucan rich ligands
can compensate in the absence of Dectin-1 [21,22]. Alter-
natively, zymosan also contains low amounts Saccharomyces
mannans, and other contaminants, and may induce inflam-
mation in a Dectin-1-independent manner. It is interesting
that particulate purified b-glucans themselves are unable to
induce this disease, and that LPS is required along with
zymosan to induce MODS, suggesting that multiple recog-
nition pathways are involved. In summary, we have addressed
the role of Dectin-1 in two models of b-glucan-rich ligand-
mediated immunomodulation and conclude that this recep-
tor plays a redundant role in these activities. Other receptors
and inflammatory systems known to be involved in recogni-
tion of b-glucans should be addressed in future work on these
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